Table 2.
List of clinical trials available at clinicaltrials.gov for the use of CBD in neurologic conditions.
| Compound | Dosage and Treatment | Condition | Phase | Status and Results | Clinical Trial Code |
|---|---|---|---|---|---|
| High CBD and low THC |
Hemp derived solution to be administered sublingually twice daily | AD and anxiety | Early 1 | Still recruiting | NCT04075435 |
| THC-free CBD oil | Starting at a dosage of 15 mg twice per day with up titration to 45 mg twice per day; oral solution | AD and dementia | 2 | Still recruiting | NCT04436081 |
| GWP42003 (purified CBD) |
Started at 5 mg/kg/day and is increased by 2.5–5 mg/kg at 3–5-day intervals to a target dose of 20 mg/kg/day; oral solution | Tremor in PD | 2 | 3 participants dropped out due to study drug intolerance. The remaining participants demonstrated improvements in cognition, depression, and emotional issues associated with PD. | NCT02818777 |
| Medical cannabis | Inhaled dried buds or sublingual oil extract | Non-motor symptoms of PD | 2 | Still recruiting | NCT05106504 |
| Nabilone | 0.25–2 mg per day. Capsules, taken orally daily |
Non-motor symptoms of PD | 2 | Positive effects on anxious mood and night-time sleep problems, with no serious adverse effects registered [154]. | NCT03769896 |
| GWP42003 (purified CBD) |
150 mg/day, increased by 150 mg/day each week for the remaining three weeks. Maximum dose of 600 mg/day during the fourth week; oral solution | Psychosis in PD | 2 | No adverse effect was observed during the treatment. Psychosis symptoms decreased [148]. | NCT02818777 |
| Epidiolex | 100 mg/mL oral solution titrated to a target maintenance dose of 20 mg/kg/day over 2 weeks | Epilepsy | 3 | The study demonstrated long-term benefits with a 43.9% reduction in monthly drop and total seizures frequency in the CBD group, observed through 156 weeks [149]. | NCT02224573 |
| CBD (nonplant-based) |
3 multiple ascending doses: 10 mg/kg/day, 20 mg/kg/day and 40 mg/kg/day; oral solution | Epilepsy | 1/2 | Short-term administration was generally safe and well tolerated. Inter-individual variability decreased with multiple doses [155]. | NCT02324673 |
| Epidiolex | Various doses between 5 mg/kg/day and 50 mg/kg/day; oral solution | Epilepsy | - | Seizure control is proportional to CBD plasma level, with a linear relationship between dosage and level of CBD [156]. | NCT02695537 |
| CBD (in corn oil) |
5–25 mg/kg/day; oral solution | Epilepsy | 3 | On-going | NCT02783092 |
| CBD (supplement with a bio-terpene complex) |
1 capsule/day (Hemp Extract 35 mg; Bio-Terpene Complex 52 mg) | Anxiety and stress | - | Not shared |
NCT05518019 |
| Cannabis oil | Single dose of CBD (300 mg) | Social anxiety disorder | - | CBD significantly decreased anxiety measured by two different scales [152]. | JCT0018004564 |